What was the origin of innoME?
innoME GmbH was founded in 2015 by employees of the Erwin Quarder Group. Thanks to a longstanding mutual project work from the Erwin Quarder Group and the Heinz-Nixdorf Professorship Munich, there has been an intensive work on a lot of innovations in the field of life-science, diagnostic and medicine technology.
The innoME GmbH as a start-up company aims to realise some of these innovations and to establish them successfully on the market.
Besides the development and the market entry of own products, innoME predominantly considers itself as a development and realisation partner for innovative products and processes.
Due to a well-positioned and ambitious team of scientists and engineers as well as being close to the Erwin Quarder Group (high-tech manufacturer of plastic-hybrid components), innoME recommends itself as a partner for the successful establishment and realisation of innovative products and processes.
|-Start of the cooperation between Erwin Quarder Systemtechik and Heinz Nixdorf Professorship for Medical Electronics of the Technical University Munich||-Start of a BMBF project with the consortium partner related to the topic "Automated High-Content-Analysis Platform for Individualised Therapy Strategies"||-Assistance in diverse research and development projects for the development, interpretation and production of plastic-hybrid components with integrated sensor technology for applications in the field of medicine||-Opening of the research, development and analysis laboratory of the company Erwin Quarder Systemtechnik for the manufacture of printed systems||-Development of production systems for the manufacture of systems in printed electronics -Implementation of a cell-analysis platform in daily clinical practice of a renowned hospital chain||-Foundation of the innoME GmbH at the Espelkamp site –Investment in a laser system for the manufacture of microstructures –Start of strategic and operative planning||-Start of the operative business, extension of the site Munich –Approval for preparatory work of a clinical study in terms of personalised tumor therapy and approval for the processing of cytostatic agents|